Centessa Pharmaceuticals plc
CNTA
$16.81
-$0.36-2.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00M | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 15.00M | -- | -- | -- | -- |
| SG&A Expenses | 12.33M | 13.71M | 12.50M | 11.17M | 13.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.78M | 74.58M | 46.41M | 43.98M | 36.09M |
| Operating Income | -30.78M | -74.58M | -46.41M | -43.98M | -36.09M |
| Income Before Tax | -24.74M | -110.28M | -41.96M | -43.11M | -37.57M |
| Income Tax Expenses | 1.40M | 1.05M | 608.00K | 705.00K | 481.00K |
| Earnings from Continuing Operations | -26.14M | -111.33M | -42.57M | -43.82M | -38.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.14M | -111.33M | -42.57M | -43.82M | -38.05M |
| EBIT | -30.78M | -74.58M | -46.41M | -43.98M | -36.09M |
| EBITDA | -30.56M | -74.49M | -46.32M | -43.90M | -35.85M |
| EPS Basic | -0.20 | -0.84 | -0.37 | -0.40 | -0.38 |
| Normalized Basic EPS | -0.12 | -0.36 | -0.23 | -0.25 | -0.23 |
| EPS Diluted | -0.20 | -0.84 | -0.37 | -0.40 | -0.38 |
| Normalized Diluted EPS | -0.12 | -0.36 | -0.23 | -0.25 | -0.23 |
| Average Basic Shares Outstanding | 133.03M | 132.05M | 116.25M | 109.49M | 99.89M |
| Average Diluted Shares Outstanding | 133.03M | 132.05M | 116.25M | 109.49M | 99.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |